Registration Open Programme Exhibition & Sponsorship Satellite Symposia
Please note that all times are in Central European Summer Time (CEST)
Programme Filter11.45
S. Vujosevic ITALY
Nomenclature of qualitative and quantitative OCTA parameters
11.53
M. Munk SWITZERLAND
Consensus on OCTA metrics in retinal vascular diseases and standardization of OCTA parameters in clinical trials
12.01
F. Pichi UAE
Consensus on OCTA metrics in inflammatory diseases
12.09
U. Chakravarthy UK
The Unicorn: Expert consensus on OCT A nomenclature in exudative AMD
12.17
Discussion
12.30
End of session
13.45
B. Bodaghi FRANCE
Overall role of local therapy and indications in NIU-PS
13.50
C. Pavesio UK
Local and/or systemic strategies: what is the best option for each patient?
13.55
Z. Habot-Wilner ISRAEL
Local therapeutic armamentarium: from A to Z
14.00
U. Pleyer GERMANY
Common complications of local therapies and their management
14.05
Q.D. Nguyen USA
Local Treatment in Development for Uveitis
14.10
M. de Smet SWITZERLAND
Best examples of therapeutic management in current practice
14.15
Discussion
14.30
End of session
14.45
T. Rossi ITALY
Welcome and Introduction
14.48
T. Hassan USA
More options for wide-field viewing — back to the future
14.51
P. Stalmans BELGIUM
First reported clinical results from end-stage RP patients implanted with an innovative 3D- neural interface retinal prosthesis
14.54
S. Charles USA
Medium term PFO for inferior RDs, giant breaks (except superior) and macular patch grafts.
14.57
T. Rossi ITALY
Novel instrument for ILM, amniotic and retinal flap manipulation
14.59
D. Steel UK
Sphere of influence and fluctuations in flow during vitrectomy – effect of cutter design
15.02
M. De Smet SWITZERLAND
Optimizing subretinal delivery via robotics
15.05
S. Rizzo ITALY
A novel multi-function instrument
15.08
Discussion
15.30
End of session
15.45
N. Hammel USA
ML for predicting conversion to neovascular AMD
15.50
P. Keane UK
Predicting AMD progression using AI
15.55
L. de Sisternes USA
AMD-related biomarker extraction from optical coherence tomography (OCT) and OCT angiography data
16.00
J.A. Hallak USA
AI in neovascular AMD: prediction of injection requirements
16.05
Joint Discussion – State-of-the-art AI-applications for exudative AMD
16.15
M. Pfau GERMANY
Beyond RPE-atrophy: novel biomarkers to characterize retinal atrophy progression
16.20
S. Gao USA
Prediction of disease progression in AMD to improve clinical trial design
16.25
Joint Discussion – Unmet needs and future directions in Geographic Atrophy
16.30
End of session
Panel: Y. Le Mer FRANCE, K. Krepler AUSTRIA, I. Relimpio SPAIN, M. Romano ITALY
08.45
C. Franco Ruedas SPAIN
Presentation 1: Retinal autograph in large refractory macular hole
08.48
Discussion
08.53
C. Iovino ITALY
Presentation 2: Human amniotic membrane plug in a patient with recurrent macular hole and atrophic AMD: what’s the best surgical approach?
08.56
Discussion
09.01
J.B. Ducloyer FRANCE
Presentation 3: Gene therapy: a new complication
09.04
Discussion
09.09
M. Sommer AUSTRIA
Presentation 4: ”Fiat Lux”- A sleeve for vitrectomy light probe modification
09.12
Discussion
09.17
F. Sabatino UK
Presentation 5: ILM flap for the optic disc pit maculopathy
09.20
Discussion
09.25
Announcement of the winner
09.30
End of session
09.45
T. Williamson UK
Introduction and Natural history of RRD
09.49
J. van Meurs THE NETHERLANDS
Pre-operative assessment and management of the macula in RRD
09.53
A. Grabowska UK
Pre-operative management of the macula in PPV for RRD
09.57
D. Yorston UK
Immediate postoperative posturing
10.01
R.J. Hillier UK
Pneumatic retinopexy vs PPV
10.05
T. Williamson UK
Management of the macular displacement and macular folds
10.09
A. Grabowska UK
PVR, retinectomy and the macula
10.13
Discussion
10.30
End of course
10.45
Introduction – YOURS committee
C. Dysli SWITZERLAND,
E. de Carvalho UK ,
L. Kuehlewein GERMANY,
R. Mastropasqua ITALY,
Y. Subhi DENMARK,
E. van Dijk THE NETHERLANDS
10.47
C. Iovino ITALY
Photodynamic therapy induced choroidal changes in central serous chorioretinopathy – experience from different countries
10.52
G. Ledesma Gil MEXICO/UK
Don’t throw your fluorescein angiography machine away yet
10.57
M. Bagger DENMARK
The hangman game of uveal melanoma
11.02
R. D’Aloisio ITALY
From smallfield to widefield OCTA in retinal vascular diseases
11.07
T. Nguyen THE NETHERLANDS
Two-year prospective follow-up in patients with CRB1-associated retinal dystrophies: paving the way towards gene therapy
11.12
T. Heeren UK
The end stage of Macular Telangiectasia type 2
11.17
Discussion and announcement of the winner of the Science Slam
11.28
Announcement winner Ophthalmologica lecture
11.30
End of session
13.30
We now know how to posture patients after detachment surgery
For: D. Yorston UK
Against: R. Hussain UK
15.30
K. Rezaei USA
Zimura trial results
15.38
P. Rosenfeld USA
Apellis trial results
15.46
P. Kaiser USA
Gene therapy for neovascular AMD update
15.54
F. Bandello ITALY
Faricimab update
16.02
Discussion
16.15
End of session
16.30
K. A. Rezaei USA
Novel Gene Therapy Approaches for Inherited Retinal Diseases
16.35
T. S. Hassan USA
MD Predictors of Endophthalmitis After Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength
16.40
A. Tufail UK
Anti-VEGF: the future is synthetic?
16.45
P. K. Kaiser USA
New anti-VEGF agents: What’s changed, What’s the same
16.50
F. Boscia ITALY
Small Gauge Surgery of Myopic Foveoschisis
16.55
S. Rizzo ITALY
Retinal Detachment: New Observations to Understand an Old Problem
17.00
Discussion
17.15
End of session
09.45
W. Schrader GERMANY
Decisions in severe ocular trauma: when to reconstruct, give up reconstruction, or refer
09.50
TBC
Post-traumatic Endophthalmitis: clinical cases
09.55
TBC
Traumatic Retinal Detachment
09.59
M. Zarbin USA
Surgery for NLP eyes after open globe injury
10.05
K. Sabti KUWAIT
The Use of Endoscopy in Severe Posterior Segment Trauma
10.10
F. Fayyad JORDAN
Severe Trauma In Children
10.15
M. Mura SAUDI ARABIA
Management of post-traumatic complications
10.20
Live Discussion Q&A; Entire Group
10.30
End of session
12.45
R. Spaide USA
Choriocapillaris Imaging: Going Deep
12.50
S. Sadda USA
OCT Imaging: What Else for the Future?
12.55
G. Cheung SINGAPORE
Imaging in Myopia: Seeing Far into the Future
13.00
J. Kim USA
Tele-Ophthalmology: Where Are We Headed?
13.05
L. Lam USA
Augmented Reality: How will it become a reality?
13.10
D. Ting SINGAPORE
AI and Ophthalmology: Sky is the Limit
13.15
Discussion
13.30
End of session
Prof. Frank G. Holz, FEBO, FARVO
University Eye Hospital Bonn
EURETINA President
Dear Colleagues,
On behalf of myself and the board of EURETINA, I would like to extend my sincere gratitude to you for supporting EURETINA 2020 Virtual by joining us for our first online meeting on 2 – 4 October. With over 8,000 registrations to the event, we are delighted with the tremendous success of the virtual format.
We hope that you enjoyed the event from the comfort of your home and please be reminded that you can watch all your favourite and missed sessions through EURETINA playback on the virtual platform over the next three months.
I would like to take this opportunity to remind you that through the course of this year, I have initiated together with the board of EURETINA a strategic Roadmap 2025 to outline the priorities of the Society moving forward. You can find a copy of the road map in your virtual briefcase on the virtual platform and website.
The virtual Congress included a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and were glad to be able to still have the opportunity to engage directly with them during the annual meeting.
We look forward to seeing you again next year at what we hope will be a live congress. However, this year has taught us that the congress can be successful no matter what the format due to the commitment of its members and supporters.
With very best wishes,
Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA
Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.
If you are an EURETINA Member or have submitted an abstract, you may already have an account.
If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.
Prices are in Euro & listed without VAT VAT is charged at 20% | EARLY FEE 5 Aug – 25 Sept | LATE FEE 26 Sept – 4 Oct |
EURETINA Member | 50 | 65 |
Non – Member | 95 | 110 |
Ophthalmic Nurse / Technician* | 50 | 65 |
*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.Registration Information
CME credits will only be awarded to those who attended the live meeting from 2-4 October 2020